Putting Electroencephalography (EEG) in the Emergency Department

Status Completed

Clinical Trial Summary

The proposed study aims to test the impact of microEEG on clinical management (diagnosis and treatment) of emergency department patients with Altered Mental Status (AMS). The study will utilize a portable, wireless, FDA-approved device (microEEG) as the intervention. Patients will be randomized to routine care plus microEEG (experimental arm) or routine care alone (control arm). The investigators hypothesize that incorporating microEEG in the work up of patients with AMS will impact the clinical management of these patients.

Clinical Trial Description

Approximately, 4% and 10% of emergency department (ED) patients in the United States present with altered mental status (AMS). According to previous studies, close to 30% of AMS cases occur due to neurological etiologies. Among these pathologies are non-convulsive seizures (NCS) and non-convulsive status epilepticus (NCSE). In our previous study, the investigators established that approximately 4% (95% confidence interval, 2-8%) of ED patients with AMS suffer from NCS and NCSE. Our study also revealed that 78% of the ED patient with AMS have some form of EEG abnormality.

NCS and NCSE are difficult to diagnose especially in AMS patients because performing a thorough physical examination or obtaining medical history is often impossible in altered patients. Definitive diagnosis of NCS/NCSE requires electroencephalography (EEG), a test that records brain electrical activity and provides information about the brain function.

Unfortunately, obtaining an EEG in the ED can be challenging. This requires transporting an EEG machine to patient's bedside, where space limitations and presence of variety of monitors and devices, especially in over-crowded EDs render this practice difficult. In many institutions an EEG service is not offered after work hours due to the unavailability of 24/7 EEG technologist coverage and real-time electroencephalographer interpretation. As a result of the aforementioned limitations, ED physicians may refrain from ordering EEG.

The wireless portable EEG device (microEEG) designed by the Bio-Signal Group was designed to address these limitations. With minimal training, ED personnel could use this small, microEEG device to obtain an EEG. The recording then can be wirelessly transmitted to a host computer via a secure network connection to the neurology experts who could interpret the EEG. Incorporating microEEG in the initial workup of patients with AMS could help the ED attending rule out NCS/NCSE and focus on other diagnoses. Alternatively, if the presence of NCS is confirmed by EEG, the treatment could be initiated early and potentially reduce morbidity or mortality.

The investigators hypothesize that incorporating EEG in the work of ED patients with AMS could impact the management(diagnosis and treatment)of these patients and influence their clinical outcome.

Sample size: Our sample size analysis using data one published related study reveled that the study would need 65 patients in each group (total n:130). However, the investigators plan to perform an interim analysis after enrolling half of this target sample and adjust the sample size calculation based on the collected data if necessary. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01671475
Study type	Interventional
Source	Bio-Signal Group Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2012
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Completed	`NCT03138876` - EEG Cap for Identification of Non-Convulsive Status Epilepticus	N/A
Enrolling by invitation	`NCT05604430` - Pre-hospital Ventilation Clinical Study
Active, not recruiting	`NCT04929704` - Diagnostic Yield and Influence on Length of Stay of Brain Computed Tomography for Elderly Patients With Altered Mental Status in an Emergency Setting
Not yet recruiting	`NCT06370442` - Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult	Phase 3
Active, not recruiting	`NCT03133208` - Sepsis Associated Encephalopathy (SAE) Biomarkers
Terminated	`NCT02950181` - Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients	N/A
Completed	`NCT03369093` - RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia	N/A
Withdrawn	`NCT01923376` - Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)	N/A
Completed	`NCT02383745` - EEG in In-hospital Patients With Seizure or Altered Mental State
Recruiting	`NCT05418634` - Point-of-care EEG in the Pediatric Emergency Department
Completed	`NCT04410757` - Point of Care Ultrasound Evaluation in the Post-Anesthesia Unit
Completed	`NCT01355211` - Putting Electroencephalography (EEG) in the Emergency Department	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.